Dmitri Sviridov

Dynamics of reverse cholesterol transport: protection against atherosclerosis.

Structure-function studies of apoA-I variants: site-directed mutagenesis and natural mutations.

Delineation of the role of pre-beta 1-HDL in cholesterol efflux using isolated pre-beta 1-HDL.

Expression of sterol 27-hydroxylase (CYP27A1) enhances cholesterol efflux.

Single session exercise stimulates formation of pre beta 1-HDL in leg muscle.

Natural mutations of apolipoprotein A-I impairing activation of lecithin:cholesterol acyltransferase.

Low-density lipoprotein receptor and apolipoprotein A-I and B expression in human enterocytes.

Expression of caveolin-1 enhances cholesterol efflux in hepatic cells.

Physical fitness and reverse cholesterol transport.

Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages.

HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport.

Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration.

Human immunodeficiency virus infection and macrophage cholesterol metabolism.

Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.

Genetic factors affecting HDL levels, structure, metabolism and function.

HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis.

ABCA1 expression in humans is associated with physical activity and alcohol consumption.

Statins and metabolism of high density lipoprotein.

The role of different regions of ATP-binding cassette transporter A1 in cholesterol efflux.

Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin.

Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.

HIV infection and high density lipoprotein metabolism.

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

Antiatherogenic functionality of high density lipoprotein: how much versus how good.

Impact of freezing on high-density lipoprotein functionality.

Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.

High-density lipoprotein reduces the human monocyte inflammatory response.

Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo.

A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis.

Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.

HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

Maturation of apolipoprotein A-I: unrecognized health benefit or a forgotten rudiment?

High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus.

Antiretroviral compounds and cholesterol efflux from macrophages.

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux.

The macrophage: the intersection between HIV infection and atherosclerosis.

HIV, atherosclerosis and inflammation: implications for treatment.

Frontiers in research series: Physiological and pathological functions of high-density lipoprotein. Introduction.

Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1.

5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux.

A gel-based method for purification of apolipoprotein A-I from small volumes of plasma.

Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.

Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation.

Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein.

Fenofibrate, homocysteine, cholesterol efflux and primum non nocere.

Global functional knockdown of ATP binding cassette transporter A1 stimulates development of atherosclerosis in apoE K/O mice.

Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus.

HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux.

Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection.